← All trials
NCT04657640
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 11, 2020
- Primary completion
- Nov 30, 2021
- Completion date
- Nov 30, 2021
- First posted
- Dec 8, 2020
- Last posted
- Jul 27, 2021
- Enrollment
- 2100
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Centre de Recherche en Sante de Nouna, Burkina FasoCollaborator
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.